Month: February 2013

GSK – ViiV Abandons Lersivirine – An Investigational NNRTI HIV Medication

Dear HIV Community Writer, ViiV Healthcare has taken the decision to stop the development program investigating the non-nucleoside reverse transcriptase inhibitor (NNRTI), lersivirine.  This is not due to any safety concerns regarding the compound. ViiV Healthcare’s goal is to support the best possible outcomes for people living with HIV, and to deliver new therapies that …

GSK – ViiV Abandons Lersivirine – An Investigational NNRTI HIV Medication Read More »

Successful treatment is “as effective as consistent condom use” in reducing HIV transmission

At least, for vaginal sex…(no data on anal sex!) The statement notes that there is now conclusive randomised clinical trial evidence, from the HPTN 052 trial, to show that transmission of HIV through vaginal sex is significantly reduced when an HIV-positive person is taking effective antiretroviral therapy (ART). In this trial, early treatment reduced HIV transmission …

Successful treatment is “as effective as consistent condom use” in reducing HIV transmission Read More »

Recent Studies Show Concerns With The Use of Tenofovir (Viread), Popular Drug in HIV Treatment

Tenofovir impairs enzyme that stops cells aging This study let us know that NRTI drugs, already known for causing the damage to mitochondrial DNA that leads to peripheral neuropathy, fat loss and some other side-effects, also exert an effect on cellular DNA, and that in this case tenofovir may be the drug to keep an …

Recent Studies Show Concerns With The Use of Tenofovir (Viread), Popular Drug in HIV Treatment Read More »

Scroll to Top